Your argument ought to be directed to Congress rather than the FDA. As mentioned in #43948, the writers of Subpart H/Subpart E did not anticipate that cancer drugs would initially be reviewed by the FDA based on survival data.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”